Utilization for premature labor of non-steroidal anti-inflammatory agent is well known for thirty years now. Since then, these molecules are regularly tested against others and proposed as efficacious tools. However their prescriptions are not so usual and easy as expected. Very often fetal risks are underlined and exacerbated. For this review of the literature we tried to present on an extensive analysis of complications encountered in clinical practice and ways of avoiding them, following the mechanism of actions of these anti prostaglandins. Perhaps in the near future use of cyclo-oxygenase-type-2-selective non-steroidal anti-inflammatory agent will resolve our dilemma. We present here possible developments.